Balyasny Asset Management
SYRS

Balyasny Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Balyasny Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Upgrade to unlock
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
2024
Q1 		$124K Buy
2022
Q3 		– Sell
2022
Q2 		$14K Buy
2018
Q2 		– Sell
2018
Q1 		$134K Sell
2017
Q4 		$285K Buy